Retropsoas Technologies
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Retropsoas Technologies sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Retropsoas Technologies: 2 sponsored US clinical trials, 1 recruiting.
Retropsoas Technologies sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is Transforaminal Lumbar Interbody Fusion Surgery, with 1 trials.
Mid-pack sponsor footprint
Retropsoas Technologies is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
A Post-marketing Study to Evaluate a Novel Surgical Monitoring Technique Using the EARP Nerve Cuff in TLIF Surgery.
NCT06204900
The Objective of the Protocol is to Generate Real World Evidence (RWE) Supporting the Safety, Performance, and Health Economics of Using the Regulatory Approved and Commercially Available EARP Interbody System Used During Lumbar Interbody Fusion (LIF) Procedures With the EARP Nerve Cuff Electrode
NCT07020000
Therapeutic Areas
What is open in the Retropsoas Technologies pipeline
1 recruiting of 2 indexed (50% open).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Transforaminal Lumbar Interbody Fusion Surgery (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Retropsoas Technologies: open-pipeline peers nationwide
Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Retropsoas Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
- Abcentra · 50% recruiting · 2 trials
Related
What to do with this Retropsoas Technologies page
2 registered trials is a research-attention snapshot, not an endorsement of Retropsoas Technologies or any single study.
- 1 of Retropsoas Technologies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Transforaminal Lumbar Interbody Fusion Surgery is the condition Retropsoas Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Transforaminal Lumbar Interbody Fusion Surgery trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Retropsoas Technologies pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.